Skip to main content

Peer Review reports

From: Galcanezumab in patients with episodic migraine: results from the open-label period of the phase 3 PERSIST study

Original Submission
18 May 2023 Submitted Original manuscript
28 May 2023 Reviewed Reviewer Report
1 Jun 2023 Reviewed Reviewer Report
13 Jun 2023 Author responded Author comments - Shengyuan Yu
Resubmission - Version 2
13 Jun 2023 Submitted Manuscript version 2
Publishing
13 Jun 2023 Editorially accepted
4 Aug 2023 Article published 10.1186/s10194-023-01613-1

You can find further information about peer review here.

Back to article page